FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Foamix Pharmaceuticals Ltd.

2 Holzman Street
Weizmann Science Park
Rehovot 7670402
972 8 931 6233

Full Time Employees80

Key Executives

NameTitlePayExercisedYear Born
Mr. David T. DomzalskiCEO & Director891kN/A1967
Mr. Ilan Hadar M.B.A., MBACFO & Country Mang.794.74kN/A1969
Ms. Mutya HarschGen. Counsel & Chief Legal Officer556kN/A1975
Dr. Darrell S. Rigel M.D., MSConsultant40.2kN/A1950
Dr. Iain A. StuartChief R&D OfficerN/AN/A1973
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Corporate Governance

Foamix Pharmaceuticals Ltd.’s ISS Governance QualityScore as of April 1, 2019 is 2. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.